LianBio is a biopharmaceutical company that designs and provides innovative drugs and treatments for oncology and cardiology diseases. The company develops nine product candidates across cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications. Its late-stage, clinically validated pipeline is comprised of five product candidates: mavacamten, TP-03, NBTXR3, infigratinib, and LYR-210.